Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The purpose of this mono therapy study is to evaluate the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of BCD-145 (JSC BIOCAD, Russia) in patients with unresectable/metastatic melanoma.

Next Previous
Trial Profile

The purpose of this mono therapy study is to evaluate the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of BCD-145 (JSC BIOCAD, Russia) in patients with unresectable/metastatic melanoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Anti-CTLA-4 monoclonal antibody (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Biocad

    • Most Recent Events

    • 23 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top